Study examines role of urate-lowering therapy on renal function in patients with hyperuricemia

Urate-lowering therapy alone may not directly reduce the risk of kidney disease in those with hyperuricemia. However, according to a study presented at the American College of Rheumatology Annual Meeting in San Diego, working to lower serum uric acid based on the 2012 American College of Rheumatology Guidelines for Management of Gout has a positive effect.

When the amount of uric acid in the blood reaches an unusually high level, it is called hyperuricemia. It has been established in previous studies that there is a connection between hyperuricemia and chronic kidney disease. There have been several small studies on the impact of urate-lowering treatments on the progression of kidney disease, and Kaiser Permanente Southern California researchers recently conducted a large study that evaluated patients with hyperuricemia and the impact of urate-lowering treatments on kidney function.

"This is the largest study with the most diverse population to examine the role of urate lowering therapy (ULT) on renal function in patients with elevated uric acid," says Gerald Levy, MD; rheumatologist, Kaiser Permanente Downey Medical Center; and lead author in the study.

Using database information from January 1, 2002 through December 31, 2010, Dr. Levy's team identified 111,992 patients with serum uric acid levels of at least 7mg/dL. To be included in the study, the patients needed to be at least 18 years old, not on dialysis, and without chronic kidney disease, HIV, non-remission cancer, proteinuria or kidney stones. Additionally, the patients must not have received an organ transplant, and they must not have taken ULT (i.e., allopurinol, probenecid and febuxostat) in the year prior to joining the study. A total of 16,186 patients were ultimately included in the study.

Patients had at least one serum uric acid and glomerular filtration rate level within six months prior to study entry and at least one of each in the follow up period. Outcome events were defined as: 30 percent or greater reduction in glomerular filtration rate, dialysis, or glomerular filtration rate falling to less than 15 ml/min. Patients were followed until an outcome event, death or withdrawl from the study.

The patients were divided into three groups. The first group (11,192 patients) was never treated with ULT; the second (3,902 patients) was on ULT less than 80 percent of the time; the third (1,092 patients) was on ULT 80 percent or more of the time. The majority of patients who took ULT during the course of the study were taking allopurinol (98.3 percent), and no one group experienced a higher percentage of deaths during the study than the other groups.

Dr. Levy's team noted that the group receiving urate-lowering therapy 80 percent or more of the time of the study tended to be older men with more co-existing diseases when compared to the other two groups. They also began the therapy earlier. For example, 43.5 percent in the over 80 percent group started the therapy within two weeks of the study compared to 16.9 percent in the less than 80 percent group and 94 percent started the therapy within six months compared to 41 percent in the less than 80 percent group.

Additionally, the team determined that age, female gender, having high blood pressure, diabetes or congestive heart failure, previous hospitalizations, having higher serum uric acid levels at the beginning of the study, and having rheumatoid arthritis were all associated with the three outcome events in the study.

Patients on urate-lowering therapy for 80 percent or more of the time of the study and achieved a serum uric acid level of 6mg/dL had a 37 percent reduction in outcome events. A serum uric acid level of less than 6 mg/dl level is the treatment goal in the 2012 American College of Rheumatology Guidelines for Management of Gout. Thus researchers believe that treating to the ACR's guidelines is an effective way of preventing and controlling kidney disease in people with hyperuricemia.

"Patients who take urate lowering therapy and achieve a serum uric acid of less than 6 milligrams per deciliter, consistent with the new ACR guidelines, demonstrate a 37 percent reduction in progression of renal disease," explains Dr. Levy. "The takeaway message here is that we can help support patients with hyperuricemia, by preventing and controlling kidney disease and maintaining treatment goals. Using our electronic health records and integrated system already in place, we can help keep patients healthy for longer and deliver continuity of care."



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Low-dose lithium attenuates kidney aging in mice